Soricimed Biopharma Inc. — Form D/A
Soricimed Biopharma Inc. of MONCTON, A3, a company, filed a Form D amendment with the SEC on 2023-01-19. The offering totals $3.7M, of which $2.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-01-19
- Form: D/A
- Accession: 0001493152-23-001806
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $3.7M
- Amount sold: $2.8M
- Remaining: $957K
- Minimum investment: $8K
- Investors: 45
- Date of first sale: 2021-07-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-431623
Issuer
- Name: Soricimed Biopharma Inc.
- CIK: 0001532755
- Entity type: Corporation
- Jurisdiction: NEW BRUNSWICK, CANADA
- Address: 18 BOTSFORD STREET, MONCTON, A3, E1C 4W7
- Phone: (506) 856-0400
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Camille Belliveau | Director | MONCTON, A3 |
| Vaughn Embro-Pantelony | Director | MONCTON, A3 |
| Paul Gunn | Director | MONCTON, A3 |
| Susan Hicks | Director | MONCTON, A3 |
| Marc Rubin | Director | Denver, CO |
| Jack Stewart | Director | MONCTON, A3 |
| Robert Bruce | Executive Officer | Las Vegas, NV |
| Paul Gunn | Executive Officer | MONCTON, A3 |
| Jack Stewart | Executive Officer | MONCTON, A3 |
| Tom Reeves | Director | MONCTON, A3 |
Other filings by this issuer (2)
More